Third -Quarter 2025 Earnings Baxter International Inc. October 30, 2025 1 Forward-Looking Statements This presentation includes forward-looking statements concerning the company's financial results (including the outlook for fourth-quarter and full-year 2025) and operational, business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the fo ...

Oct 30, 2025 7:15 AM Eastern Daylight Time Baxter Reports Third-Quarter 2025 Results Share DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. "I joined Baxter because it's a global healthcare leader – an iconic brand with an essential portfolio that touches more than 350 million patients every year,†said Andrew Hider, president and CEO. "In my first weeks, I've seen firsthand the passion and expertise that ...

Core Insights - Baxter International Inc. has launched the Welch Allyn Connex 360 Vital Signs Monitor, which has received FDA's 510(k) clearance and is now available for order in the U.S. [2][11] - The launch is expected to enhance Baxter's Front Line Care unit within the Healthcare Systems & Technologies segment and strengthen its position in the connected patient monitoring market [3][10]. Product Details - The Connex 360 monitor features advanced connectivity, customizable configurations, and automated clinical documentation to streamline clinician workflows [6][7]. - It captures vital signs for adult, pediatric, and neonate patients, including blood pressure, temperature, pulse rate, respiration rate, and blood oxygen levels, enabling care teams to obtain a full set of patient vitals in under a minute [7][8]. Market Context - The global patient monitoring devices market was valued at $50.36 billion in 2024 and is projected to reach $118.21 billion by 2033, growing at a CAGR of approximately 10.2% [9]. - The increasing demand for monitoring devices and the need for continuous monitoring are key factors driving market growth [9]. Financial Performance - Baxter currently has a market capitalization of $11.92 billion and an earnings yield of 10.6%, significantly higher than the industry average of 0.2% [5]. - Despite the positive outlook from the product launch, Baxter's shares have declined nearly 2.5% following the announcement and have lost 40.2% over the past year [4][13].